NCT00111423已完成2 期
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI) in Subjects With Rheumatoid Arthritis (RA)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 216
- 主要终点
- Treatment-emergent adverse events
研究概览
简要总结
The purpose of this study is to evaluate the safety of an additional 28 weeks of treatment with pegsunercept for subjects who have completed treatment in a previous double-blind study (20000201 or 20000198). In addition, this study will evaluate the efficacy and the feasibility of subject self-administration on an outpatient basis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who have completed 24 weeks of double-blind treatment in a previous protocol (20000201 or 20000198) - Females of childbearing potential and males must practice adequate contraception, in the judgement of the investigator, during the course of the study - The subject or legally acceptable representative must give informed consent for participation in the study before any study specific procedures are performed
排除标准
- •Greater than a 7-day duration from the week 24 visit in the previous study to the first dose in this study - Any medical disability or condition (e.g., evidence of clinically significant liver dysfunction, active infection requiring treatment with systemic anti-infective agents) that would interfere with the assessment of safety of the study material or would compromise the ability of the subject to provide adequate informed consent - Concurrent treatment with an investigational agent
结局指标
主要结局
Treatment-emergent adverse events
次要结局
- Description of RA assessment outcomes
- Assessment of Compliance
研究者
相似试验
已完成
4 期
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).Hepatitis B, ChronicNCT00435825Hoffmann-La Roche551
已完成
4 期
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infectionHepatitis C, ChronicNCT00353418Hoffmann-La Roche415
已完成
3 期
A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)Hepatitis B, ChronicNCT01095835Hoffmann-La Roche131
已完成
3 期
Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive DisorderMajor Depressive DisorderNCT01355081Takeda366
已完成
2 期
A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid ArthritisArthritis, RheumatoidNCT00393146GlaxoSmithKline57